KRAS and neoplasm: While regular NSAID use was associated with a 31% lower risk of CRC in all patients, analysis by molecular subtype showed that the risk reduction was greater in microsatellite stable compared to microsatellite instability (MSI)-high cancers; in BRAF-WT compared to BRAF-mutant and in Kirsten rat sarcoma viral oncogene homologue gene (KRAS)-WT tumours.